08:04 AM EDT, 05/23/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Friday said it is presenting positive survival and clinical benefit data in three clinical poster presentations and one publish-only abstract at the American Society of Clinical Oncology (ASCO) Meeting taking place May 30 - June 3 in Chicago.

"We are highly encouraged by the survival and clinical benefit data from our Phase 2 Bria-IMT study which meets and outperforms outcomes seen with FDA approved therapies - despite our patients being more heavily pre-treated," said Dr. William Williams, BriaCell's chief executive. "These results reinforce our belief in Bria-IMT's potential to address the urgent, unmet needs of patients with metastatic breast cancer and we look forward to confirming results in our ongoing pivotal Phase 3 study."